ACM
AMRX icon

Accent Capital Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Accent Capital Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-600
Closed -$7.56K – 338
2025
Q4 		$7.56K Buy
+600
New +$6.87K ﹤0.01% 232

Other funds holding AMRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Accent Capital Management's AMRX Position: Q1 2026 in Review

Accent Capital Management sold out of Amneal Pharmaceuticals (AMRX) in Q1 2026, closing a stake of 600 shares — an estimated $7.56K sold.

Accent Capital Management first reported a position in AMRX in Q4 2025 and held it in 1 quarter. The position peaked at $7.56K in Q4 2025. 315 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

  • Accent Capital Management reported no remaining Amneal Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Accent Capital Management sold 600 Amneal Pharmaceuticals shares in Q1 2026, an estimated $7.56K.
  • Accent Capital Management first reported a position in Amneal Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Accent Capital Management's Amneal Pharmaceuticals position peaked at $7.56K in Q4 2025.
  • 315 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on Accent Capital Management's 13F filing for Q1 2026, filed 11 May 2026.